Literature DB >> 15958767

Etanercept in treatment of Felty's syndrome.

A Ghavami, S Genevay, T Fulpius, C Gabay.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15958767      PMCID: PMC1755563          DOI: 10.1136/ard.2004.032110

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  7 in total

Review 1.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

2.  [Rituximab for treatment of Felty’s syndrome].

Authors:  H Becker; H Appel; T Fassbinder; D Heitzmann; P Willeke; A M Jacobi
Journal:  Z Rheumatol       Date:  2014-06       Impact factor: 1.372

3.  Antitumor necrosis factor-induced neutropenia: a case report with double positive rechallenges.

Authors:  E Montané; M Sallés; A Barriocanal; E Riera; J Costa; X Tena
Journal:  Clin Rheumatol       Date:  2006-10-10       Impact factor: 2.980

4.  The Diagnosis Felt(y) Right: A Case Report of Felty Syndrome With Limited Articular Involvement.

Authors:  Victor E Serrano Santiago; Zack Morgan
Journal:  Cureus       Date:  2022-04-29

Review 5.  Giant Cell Arteritis: 2018 Review.

Authors:  Anne Winkler; David True
Journal:  Mo Med       Date:  2018 Sep-Oct

Review 6.  Porto-Sinusoidal Vascular Disease as the Cause of Portal Hypertension in Felty's Syndrome: A Case Report and Literature Review.

Authors:  Song Yang; Min Quan; Yue Li; Calvin Qian Pan; Huichun Xing
Journal:  Biomed Res Int       Date:  2020-07-01       Impact factor: 3.411

7.  Phenotypic variability in a child with Felty's syndrome: a case report.

Authors:  Guo-Min Li; Hai-Mei Liu; Wan-Zhen Guan; Yi-Fan Li; Hong Xu; Li Sun
Journal:  BMC Pediatr       Date:  2020-04-07       Impact factor: 2.125

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.